IL126314A - Monoclonal antibodies having an antigen binding region specific for the extracellular domain of prostate specific membrane antigen (psma) - Google Patents

Monoclonal antibodies having an antigen binding region specific for the extracellular domain of prostate specific membrane antigen (psma)

Info

Publication number
IL126314A
IL126314A IL12631497A IL12631497A IL126314A IL 126314 A IL126314 A IL 126314A IL 12631497 A IL12631497 A IL 12631497A IL 12631497 A IL12631497 A IL 12631497A IL 126314 A IL126314 A IL 126314A
Authority
IL
Israel
Prior art keywords
psma
monoclonal antibodies
extracellular domain
binding region
antigen
Prior art date
Application number
IL12631497A
Other languages
English (en)
Other versions
IL126314A0 (en
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24490004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL126314(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Publication of IL126314A0 publication Critical patent/IL126314A0/xx
Priority to IL15579303A priority Critical patent/IL155793A0/xx
Publication of IL126314A publication Critical patent/IL126314A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12631497A 1996-03-25 1997-03-25 Monoclonal antibodies having an antigen binding region specific for the extracellular domain of prostate specific membrane antigen (psma) IL126314A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL15579303A IL155793A0 (en) 1996-03-25 2003-05-06 Monoclonal antibodies having an antigen binding region specific for the extracellular domain of prostrate specific membrane antigen (psma)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62139996A 1996-03-25 1996-03-25
PCT/US1997/005214 WO1997035616A1 (en) 1996-03-25 1997-03-25 Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen

Publications (2)

Publication Number Publication Date
IL126314A0 IL126314A0 (en) 1999-05-09
IL126314A true IL126314A (en) 2003-07-31

Family

ID=24490004

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12631497A IL126314A (en) 1996-03-25 1997-03-25 Monoclonal antibodies having an antigen binding region specific for the extracellular domain of prostate specific membrane antigen (psma)

Country Status (10)

Country Link
EP (1) EP0914155B1 (ja)
JP (1) JP4295826B2 (ja)
AT (1) ATE318147T1 (ja)
AU (1) AU725583B2 (ja)
CA (1) CA2250141C (ja)
DE (1) DE69735294T2 (ja)
DK (1) DK0914155T3 (ja)
ES (1) ES2260788T3 (ja)
IL (1) IL126314A (ja)
WO (1) WO1997035616A1 (ja)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070782B1 (en) 1992-11-05 2006-07-04 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
US6953668B1 (en) 1992-11-05 2005-10-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US6569432B1 (en) 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
EP0812356B1 (en) 1995-02-24 2006-02-08 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6150508A (en) * 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
GB2328871A (en) * 1997-09-05 1999-03-10 Merck & Co Inc Compositions for inhibiting platelet aggregation
WO1999043710A1 (en) * 1998-02-26 1999-09-02 Beckman Coulter, Inc. Prostate-specific membrane antigens and methods of making and using
ATE437947T1 (de) * 1998-06-01 2009-08-15 Agensys Inc Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
WO2000050457A1 (en) * 1999-02-22 2000-08-31 Beckman Coulter, Inc. Prostate-specific membrane antigens and methods of making and using
EP1710256A1 (en) * 1999-07-29 2006-10-11 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen
ES2277846T3 (es) * 1999-07-29 2007-08-01 Medarex, Inc. Anticuerpos monoclonales humanos para antigeno prostatico especifico.
FR2797743B1 (fr) * 1999-08-23 2003-08-08 Urogene Lignee cellulaire prostatique et son utilisation pour l'obtention d'une tumeur prostatique etablie chez l'animal
US6653129B1 (en) * 1999-09-13 2003-11-25 The Regents Of The University Of Colorado Method for isolation of cells from a solution
JP4838436B2 (ja) * 2001-04-04 2011-12-14 積水メディカル株式会社 抗ヒト肝性トリグリセリドリパーゼ抗体
AU2002318169B2 (en) 2001-06-01 2007-10-18 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2003024388A2 (en) 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
EP2363404B8 (en) * 2001-10-23 2016-12-07 PSMA Development Company L.L.C. PSMA antibodies
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
US20040161776A1 (en) * 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
ATE408712T1 (de) 2003-01-10 2008-10-15 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
BRPI0607796A2 (pt) 2005-02-18 2009-06-13 Medarex Inc composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
EP1726650A1 (en) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
NZ566395A (en) 2005-09-26 2012-03-30 Medarex Inc Human monoclonal antibodies to CD70
EP1996716B1 (en) 2006-03-20 2011-05-11 The Regents of the University of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
WO2009106101A1 (en) * 2008-02-29 2009-09-03 Interuniversitair Microelektronica Centrum Cell-enzyme based biosensors
PL2326350T3 (pl) 2008-09-08 2014-03-31 Psma Dev Company L L C Związki do zabijania eksprymujących PSMA, opornych na taksan komórek rakowych
ES2712732T3 (es) 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
CA2782333C (en) 2009-12-02 2019-06-04 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
RU2610336C2 (ru) 2011-04-21 2017-02-09 Сиэтл Дженетикс, Инк. Новые конъюгаты связывающее соединение - активное соединение (adc) и их применение
JP2014518615A (ja) 2011-04-22 2014-08-07 エマージェント プロダクト デベロップメント シアトル， エルエルシー 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法
CA2934617A1 (en) 2013-12-23 2015-07-02 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with kinesin spindle protein (ksp)
JP6971858B2 (ja) 2015-06-22 2021-11-24 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ）
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
SG10201913625XA (en) 2015-08-07 2020-03-30 Imaginab Inc Antigen binding constructs to target molecules
EP3352760A4 (en) 2015-09-21 2019-03-06 Aptevo Research and Development LLC CD3 BINDING POLYPEPTIDES
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
MX2018011627A (es) 2016-03-24 2019-01-10 Bayer Pharma AG Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles.
CN109310781B (zh) 2016-06-15 2024-06-18 拜耳制药股份公司 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc)
CA3047491A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
EP3558387B1 (de) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
CA3093078A1 (en) 2018-03-06 2019-09-12 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof
SG11202012342WA (en) 2018-06-18 2021-01-28 Eureka Therapeutics Inc Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
ES2934963T3 (es) 2018-07-31 2023-02-28 Heidelberg Pharma Res Gmbh Anticuerpos humanizados contra PSMA

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE342356T1 (de) * 1992-11-05 2006-11-15 Sloan Kettering Inst Cancer Prostata-spezifisches membranantigen
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
EP0812356B1 (en) * 1995-02-24 2006-02-08 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof

Also Published As

Publication number Publication date
WO1997035616A1 (en) 1997-10-02
IL126314A0 (en) 1999-05-09
ES2260788T3 (es) 2006-11-01
EP0914155A4 (en) 2001-05-16
DE69735294D1 (de) 2006-04-27
EP0914155A1 (en) 1999-05-12
AU2555297A (en) 1997-10-17
JP4295826B2 (ja) 2009-07-15
CA2250141C (en) 2008-07-29
DE69735294T2 (de) 2006-09-21
ATE318147T1 (de) 2006-03-15
AU725583B2 (en) 2000-10-12
JP2001503601A (ja) 2001-03-21
DK0914155T3 (da) 2006-06-26
EP0914155B1 (en) 2006-02-22
CA2250141A1 (en) 1997-10-02

Similar Documents

Publication Publication Date Title
IL126314A (en) Monoclonal antibodies having an antigen binding region specific for the extracellular domain of prostate specific membrane antigen (psma)
IL138497A0 (en) Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
NZ337413A (en) Antibodies that bind to Prostate Stem Cell Antigen (PSCA) to treat prostate cancer.
AU733544C (en) Treatment and diagnosis of cancer
ES2293973T3 (es) Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
IL148113A0 (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
WO1994016094A3 (en) Recombinant anti-vla4 antibody molecules
NZ288235A (en) Monoclonal antibody directed against the receptor tyrosine kinase flt4 and use in diagnosis and therapy
IL116617A0 (en) Monoclonal antibodies specific for advanced glycosylation endproducts in biological samples
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
NZ305083A (en) Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response
ES2142070T3 (es) Utilizacion de un complejo ficobiliproteina-peptido de enlace como trazador fluorescente.
HK1080091A1 (zh) 用於單獨測定scca同形異構體的免疫測定法
GR3031607T3 (en) Selective system scan for multizone radiotelephone subscriber units.
AU1971295A (en) Humanized monoclonal antibodies against human interleukin-4
WO2000032635A3 (en) Tumor specific human monoclonal antibodies and methods of use
TW288020B (en) Monoclonal antibodies specific to methamphetamine, hybridoma producing the antibodies, kits containing the antibodies and uses thereof
Pattaramalai The interaction of oral squamous cell carcinoma cells with laminin: identification of a laminin sequence that promotes cell adhesion by an integrin receptor
SE9500148D0 (sv) Antibodies for use in cancer therapy and diagnosis
DE69504991D1 (de) Verfahren zur bestimmung des lysingehaltes von samen
ZA200200730B (en) Human monoclonal antibodies to prostate specific membrane antigen.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired